CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,988,370 | -30.0% | 594,978 | +2.0% | 0.00% | -25.0% |
| Q2 2023 | $18,542,408 | +37.3% | 583,278 | +5.4% | 0.00% | +33.3% |
| Q1 2023 | $13,500,865 | -20.4% | 553,541 | +3.0% | 0.00% | -25.0% |
| Q4 2022 | $16,954,516 | +17.8% | 537,556 | +5.6% | 0.00% | +33.3% |
| Q3 2022 | $14,392,000 | +8.5% | 509,276 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $13,269,000 | -7.7% | 501,877 | +22.2% | 0.00% | 0.0% |
| Q1 2022 | $14,375,000 | +3.9% | 410,618 | -3.8% | 0.00% | +50.0% |
| Q4 2021 | $13,838,000 | +13.2% | 426,838 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $12,224,000 | +25.6% | 414,369 | +9.1% | 0.00% | 0.0% |
| Q2 2021 | $9,729,000 | +917.7% | 379,781 | +445.7% | 0.00% | – |
| Q1 2021 | $956,000 | -12.4% | 69,601 | +5.8% | 0.00% | – |
| Q4 2020 | $1,091,000 | – | 65,805 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |